Our COVID-19 Research
In collaboration with Cochrane France; commissioned by WHO Health Emergencies Programme (WHE); Cochrane Response is part of the operating team of the COVID-19 living systematic review and network meta-analysis initiatiative. COVID-NMA is an international initiative working in conjunction with the World Health Organization (WHO), led by a team of researchers from Cochrane and other institutions (Université de Paris, Inserm, CNRS, Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark, Odense University Hospital, Epistemonkos Foundation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan). The COVID-NMA initiative has three overarching parts: | |
Rapid reviews on treatments for COVID-19: HydroxychloroquineRapid reviews on treatments for COVID-19: Lopinavir/ritonavir | In collaboration with Cochrane France; commissioned by WHO Health Emergencies Programme (WHE); We deliviered evidence summaries for these rapid reviews to the comissioner |
Changing physical environments to change behaviours to reduce transmission of SARS-CoV-2 | Commissioned by the UK Innovation and Research, Economic and Social Research Council; Scoping review and rapid review: Encouraging behaviour change to reduce COVID-19 transmission: A summary of two rapid evidence reviews |
COVID-19 DTA rapid reviews | Contributing towards updates of the following Cochrane rapid reviews: |